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Abstract
Background: Excessive collection of platelets is an unwanted side effect in current centrifugation-based peripheral blood
progenitor cell (PBPC) apheresis. We investigated a novel microchip-based acoustophoresis technique, utilizing ultrasonic
standing wave forces for the removal of platelets from PBPC products. By applying an acoustic standing wave field onto a
continuously flowing cell suspension in a micro channel, cells can be separated from the surrounding media depending on
their physical properties.
Study Design and Methods: PBPC samples were obtained from patients (n=15) and healthy donors (n=6) and sorted on
an acoustophoresis-chip. The acoustic force was set to separate leukocytes from platelets into a target fraction and a waste
fraction, respectively. The PBPC samples, the target and the waste fractions were analysed for cell recovery, purity and
functionality.
Results: The median separation efficiency of leukocytes to the target fraction was 98% whereas platelets were effectively
depleted by 89%. PBPC samples and corresponding target fractions were similar in the percentage of CD34+ hematopoetic
progenitor/stem cells as well as leukocyte/lymphocyte subset distributions. Median viability was 98%, 98% and 97% in the
PBPC samples, the target and the waste fractions, respectively. Results from hematopoietic progenitor cell assays indicated
a preserved colony-forming ability post-sorting. Evaluation of platelet activation by P-selectin (CD62P) expression revealed a
significant increase of CD62P+ platelets in the target (19%) and waste fractions (20%), respectively, compared to the PBPC
input samples (9%). However, activation was lower when compared to stored blood bank platelet concentrates (48%).
Conclusion: Acoustophoresis can be utilized to efficiently deplete PBPC samples of platelets, whilst preserving the target
stem/progenitor cell and leukocyte cell populations, cell viability and progenitor cell colony-forming ability.
Acoustophoresis is, thus, an interesting technology to improve current cell processing methods.
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Introduction
Hematopoietic stem cell transplantation is a well-established
therapy for haematological malignancies and other diseases [1–3].
Currently, peripheral blood progenitor cells (PBPC), which can be
collected from the blood after a mobilization treatment, are used for
the majority of transplantations [4–6]. Standard apheresis technology
utilizessizeand densitycentrifugationinacontinuous-flowprocedure
to separate the leukocyte population from whole blood while the
remaining blood components are returned to the donor [7,8].
Administration of hematopoietic growth factors, which is
required for effective progenitor cell mobilization from the bone
marrow into the blood, has been reported to decrease platelet
counts in healthy donors before apheresis [9]. Furthermore, an
unwanted and difficult to avoid side effect of current centrifuga-
tion-based PBPC apheresis is the excessive collection of platelets
which leads to an additional, potentially clinically significant
depletion of donor platelet levels and, consequently, an increased
bleeding risk [10–13]. In addition, excessive platelet contamina-
tion of PBPC leads to difficulties in PBPC processing and may
have a negative impact on the performance (yield and purity) of
cell product manipulation, such as selection or depletion of specific
cell subsets [14,15]. Therefore, removal of platelets from PBPC for
retransfusion to the donor would considerably improve both,
donor safety as well as PBPC product quality.
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23074Microfluidic devices have shown great potential in the field of
complex biofluids such as blood [16]. The special conditions
present in the micro domain enable multiple attractive features
such as small volumes, laminar flow and fast reaction times [17].
This can be utilized in applications where cells can be manipulated
in continuous flow systems [18] or retained for further operations
using external forces or pure microfluidic phenomena [19].
The use of acoustic forces has recently emerged as a non contact
and label free method of cell manipulation [20]. When cells or
particles are subjected to an acoustic standing wave field they are
exposed to radiation forces, which will induce a movement of the
particle. Depending on the physical properties of the particles
versus the surrounding medium, the particles are moved either to
the pressure node or to the anti node of the sound field. By
applying the standing wave field over a micro channel in which a
suspension is flowing, the acoustic field acts as a filter which
produces bands of particles located at the positions of the pressure
nodes. Because of the laminar flow the particles keep their position
in the band even after they have passed through the sound field,
which enables separation of the particles from the surrounding
medium [21]. By using a standing wave of half a wavelength,
suspended particles will gather in a band located in the center of
the micro channel (Figure 1A). If the separation channel ends in a
trifurcation, the particles will exit through the center branch while
excess fluid exits through the side branches [22].
The laminar flow also enables medium switching as the acoustic
force can be used to move particles from one suspension into a
medium flowing in parallel [23]. This can be used to purify
samples by transferring the particles into a clean buffer from a
contaminated buffer [24,25].
The acoustic force on a particle is also size-dependent as the force
is proportional to the volume. This can be utilized as a fractionation
step as larger particles are transported to the pressure node faster
than smaller ones. By tuning the acoustic power and the flow rate it
becomes possible to sort out the larger particles [26,27].
A combination of the medium switching and the size dependent
fractionation mentioned above is used in the current study in
which we investigated the performance of the acoustophoresis
technique for platelet removal, aiming to efficiently deplete PBPC
samples of intact platelets whilst preserving the composition and
functionality of the collected target cells.
Results
Acoustophoretic cell separation
PBPC samples were obtained from 2 healthy donors and 8
patients for evaluation of acoustophoretic cell separation efficien-
cy. For each PBPC sample, 6–12 sample portions of the separated
target and waste fraction, respectively, were sequentially collected
for analysis. (Table 1). The median separation efficiency of white
blood cells (WBC), i.e. the median relative number of separated
WBC that was collected in the target fractions, was 97.8% (range
80–100%) and the median platelet depletion was 89.0% (range
57–100%). The separation efficiency for individual PBPC samples
is presented in Figure 2. The WBC separation efficiency to the
target fraction was .95% in all but two samples (sample no. 1 and
10) in which however the higher loss of WBC to the waste fraction
was coupled to a complete depletion (100%) of platelets from the
target fraction, which was observed in only these two samples. All
but three PBPC products were separated on the day of
leukapheresis and platelet depletion for these products was
generally higher than 90%. Overnight storage, on the other hand,
resulted in considerably lower platelet depletion as low as 70% and
,60% after storage at room temperature and 4uC, respectively
(sample nos. 5, 7 and 8). However, insufficient platelet depletion
was also observed for two of the freshly processed samples (nos. 4
and 9) that had very high platelet concentrations ($150610
3/ml).
The separation of WBC was not influenced by storage, as
reflected by a WBC separation efficiency of $98% to the target
fractions of the stored samples.
Figure 1. Acoustophoresis chip design. A) Schematic diagram of the acoustophoresis chip. Apheresis sample enters the channel from the side
channels. Wash buffer enters the chip from the central inlet. The transducer generates an acoustic standing wave between the channel walls and the
suspended cells are moved by the acoustic force into the pressure node located in the centre of the channel. As the acoustic force on a cell is size
dependent, the larger leukocytes experience a higher radiation force than the smaller platelets. B) Microscope image of the separation process taken
at the trifurcation. The larger leukocytes (WBC) have been centered in the channel by the ultrasonic standing wave and are collected in the central
outlet, while the smaller platelets (PLT) are less acoustically affected and exit through the side branches. A movie of the platelet separation process is
provided in the supplementary material.
doi:10.1371/journal.pone.0023074.g001
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Cytospins from PBPC samples (n=4) were prepared before and
after acoustophoresis separation for evaluation of cell morphology
(Table 2). The distribution of leukocyte populations in the PBPC
samples and target fractions were comparable (p.0.1).
The median relative number of granulocytes/monocytes was
70% (range 60–78%) versus 68% (50–73%) and the median
relative number of lymphocytes was 17% (range 16–28%) versus
20% (range 15–39%) in the PBPC samples and target fractions,
respectively. The very small total number of leukocytes which were
lost in the waste fraction comprised mainly lymphocytes (median
50%, range 0–91%).
Flow cytometry analysis of PBPC samples (n=3) before and
after acoustophoretic separation revealed a similar (p.0.1)
distribution of leukocyte populations in the PBSC samples and
target fractions. The median relative number of CD14 + cells was
43% (range 39–47%) versus 45% (range 40–47%), the median
relative number of CD3+ cells was 16% (range 7.2–24%) versus
17% (range 9.7–24%) and the median relative number of CD34+
cells was 2.5% (range 1.5–3.4%) versus 2.3% (range 1.0–3.1%), in
the PBSC samples and target fractions respectively. The few
leukocytes that were detected in the waste fraction were mainly
lymphocytes (median 38%, range 8.3–68%). The median viability,
as measured by PI-negativity, was 98% (range 97–99%) and 98%
(range 97–99%) in the PBPC samples and target fractions,
respectively.
Progenitor cell colony-forming ability
Cells from PBSC samples (n=9) were plated in methylcellulose
before and after acoustophoretic separation and evaluated for
colony-forming ability (Figure 3). Results were comparable
(p.0.1) in PBPC samples and target fractions, indicating a
preserved clonogenic capacity post-sorting, with a median number
of colonies/1,000 plated cells of 17 (range 9–30) in the PBPC
samples and 17.5 (range 8–25) in the target fractions, respectively.
Platelet activation
Analysis of platelet activation was performed on cells from
PBPC samples (n=5) before and after acoustophoretic separation,
using the a-granule membrane protein CD62P (P-selectin) as an
activation marker (Figure 4). In flow cytometry analysis, a major
population of CD61+ single platelets was observed, with a variable
relative number of CD61+/CD62P+ events in each sample. There
was a significant increase (p,0.1) in the median relative number of
single platelets expressing CD62P in the target (19%, range 12–
41%) and waste fractions (20%, range 8–31%), respectively, as
compared to the PBPC samples (9.0%, range 4–17%). In control
samples (n=4) obtained from standard buffy coat (BC) platelet
concentrates, however, the median relative number of activated
platelets (48%, range 40–60%) was significantly higher than in the
acoustophoretically separated fractions (p,0.05). Stimulation of
platelets with TRAP resulted in significant (p,0.1) increases in the
relative numbers of CD62P+ platelets in the waste fractions
(median 74%, range 65–86%), which were comparable to
activation levels observed in BC platelet concentrates (median
82%, range 79–85%). Activated platelets bound to leukocytes, i.e.
CD62P+/CD45+ events that were observed in the PBPC samples,
were almost exclusively separated to the target fractions.
Acoustophoresis, however, did not increase the formation of
platelet-leukocyte aggregates (Figure 5).
Discussion
The excessive collection of platelets using current centrifuga-
tion-based PBPC apheresis presents a problem in PBPC
processing, with a negative impact on the performance (yield
and purity) of cell product manipulation, such as selection or
depletion of specific cell subsets [14,15,28,29]. Furthermore,
PBPC apheresis-related co-collection of platelets causes a poten-
tially clinically significant reduction of donor platelet levels, which
translates into an increased risk of severe procedure-induced
thrombocytopenia. This is especially relevant for patients
undergoing PBPC apheresis for autologous transplantation with
already reduced pre-apheresis counts due prior cytostatic treat-
ment and mobilizing chemotherapy [10–13].
Based on recent developments in the use of acoustic forces in
cell separation [20–27], we have investigated a micro-chip based
acoustophoretic platform for the removal of platelets from PBPC
products for retransfusion to the PBPC donor. By applying an
acoustic standing wave field on to the continuously flowing PBPC
suspension, leukocytes could be almost exclusively separated to the
target fraction (98%) whereas platelets were efficiently depleted
(89%). The size dependent fractionation of leucocytes versus
platelets was accomplished by tuning the acoustic power such that
the larger leukocytes (5–20 mm in diameter) [30] were focused into
the center of the micro channel while the smaller platelets (2–4 mm
in diameter) [31] were left unaffected and remained at the lateral
walls (Figure 1B). As could be expected, the few leukocytes that
were not focused toward the channel center and thus, lost to the
waste fraction, were mainly lymphocytes (5–10 mm in diameter),
which are smaller and less acoustically affected than the larger
granulocytes/monocytes. However, the total loss of lymphocytes
to the waste fraction was minimal and thus would not be of any
clinical significance. Furthermore, composition of leukocyte
populations was conserved with a comparable median relative
number of lymphocytes, CD3+ cells, CD4+ cells, CD8+ cells,
Table 1. Acoustophoretic Cell Separation.
{
PBPC sample Target Waste
Cell counts
{
WBC (610
3/ml) 13.4 (7.2–23.3) 6.1 (1.9–15) 0.1 (0–0.4)
PLT (610
3/ml) 86.5 (16–314) 8.0 (0–61) 31.0 (0–128)
RBC (610
6/ml)
# ,0.1 ,0.1 ,0.1
Lymph (610
3/ml) 3.1 (1.9–13.7) 1.5 (0.2–9.1) -
Cell numbers
1
WBC (610
5) 13.4 (7.2–23.3) 7.8 (2.4–18.7) 0.2 (0–0.8)
PLT (610
5) 86.5 (16–314) 10.2 (0–78) 62.0 (0–256)
RBC (610
8)- - -
Lymph (610
5) 3.1 (1.9–13.7) 1.9 (0.3–11.6) -
Distribution of separated cells
WBC (%) 97.8 (80–100) 2.9 (0–22)
PLT (%) 12.5 (0–54.6) 89.0 (56.7–100)
Abbreviations: WBC, white blood cells; PLT, platelets; RBC, red blood cells;
Lymph, lymphocytes.
{Data are presented as the median (range) of 10 samples.
{The PBPC samples were diluted 1:5 before cell count.
#The RBC count was below the detection limit of 0.1 (610
6/ml) given in the
instrument manual [44].
1The addition of wash buffer to the acoustophoresis-chip and the difference in
flow rate between the central outlet (20 ml/min) and the side oultlet (2620 ml/
min), gave a sample dilution so that the cells of 100 ml PBPC sample were
distributed to 128 ml target sample (central outlet) and 200 ml waste sample
(side outlet). Cell numbers were calculated accordingly.
doi:10.1371/journal.pone.0023074.t001
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PBPC samples and the target fractions.
A possible negative influence of acoustophoresis on cell viability
could be excluded as cell viability post sorting was not different
from pre-sorting values. Furthermore, colony-forming ability,
which is a sensitive assay for functional capacity of early
hematopoietic progenitor cells, was not affected by the acousto-
phoresis procedure.
As previously described, RBC (7 mm in diameter, density
1.100 g/mL) and platelets (2–4 mm in diameter, density 1.058 g/
mL) [30,31] which behave similarly in an acoustic force field can
be efficiently separated by adjusting the suspending medium
density with cesium chloride [26]. In our study, where the acoustic
force was tuned to optimize platelet depletion without loss of target
cells, the RBC were distributed to the target fractions, as detected
by inspection of cytospin slides (data not shown). No RBC
hemolysis was evident by visual inspection of acoustophoresis
separated samples. As RBC contamination is generally low in
PBPC apheresis products and seldom presents a problem in cell
processing or transplantation [10,11,13], the issue of RBC was not
further addressed in this study.
The alpha-granule membrane protein P-selectin (CD62P) is a
widely used marker for detection of platelet activation [32–37]. In
this study, CD62P was applied for the evaluation of acoustophor-
esis-induced platelet stress, in a modified flow cytometry assay
designed to minimize artefactual activation of the samples
[35,36,38]. The low level of platelet activation that was seen in
collected PBPC apheresis samples (9%) was increased in the
acoustophoretically separated target (20%) and waste fractions
(19%), respectively, however not to the extent observed in BC
platelet concentrates that are routinely used for clinical transfu-
sion. Acoustophoresis separated platelets furthermore showed a
preserved activation capacity as indicated by an adequate response
to the stimulation with TRAP, which can induce full platelet
degranulation without initiating coagulation [32].
Our findings of platelet activation induced by acoustophoretic
cell separation were well in agreement with previous reports on
platelet activation in standard centrifuge-based cell apheresis
technology, where activation levels ranging from 10–30% of the
collected platelets are seen with different cell separators. Also in
PBPC apheresis, significant platelet activation may be induced as
shown by the detection of CD62P positive platelets in the
circulation of donors [41]. Considering furthermore the relatively
high activation rate of 20–45% in BC platelet preparations as
described by others [34,35,39,40] and as confirmed by our data
presented herein, it appears unlikely that infusion of acoustophor-
etically separated platelets would confer a higher risk of
thrombotic complications compared to current standard platelet
Figure 2. Separation efficiency of individual PBPC samples. A) The relative numbers (expressed as %) of separated WBC and platelets,
respectively, which were distributed to the target fraction are given as the mean 6 SD of 6–12 sequentially collected target portions of each PBPC
sample. B) The WBC and PLT counts of individual PBPC samples diluted 1:5 before separation. Samples were obtained from 2 healthy donors (sample
no. 5 and 9) and 8 patients (multiple myeloma, n=1; non Hodgkin lymphoma, n=4; mantle cell lymphoma, n=1; testicular cancer, n=1; or multiple
sclerosis, n=1).
doi:10.1371/journal.pone.0023074.g002
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transfusion.
The possible adverse effects, infusing PBPC products containing
activated platelets has to be considered. Adhesion of CD62P
expressing platelets to circulating leukocytes has been suggested to
play an important role in the pathogenesis of inflammatory events
[42]. Larger platelet-platelet or platelet-leukocyte aggregates,
which are sometimes visible in platelet rich PBPC products, may
also present a risk of harmful effects to the recipient. The negative
impact of high platelet numbers on target cell yield in immuno-
magnetic cell selection has also been attributed to platelet-
leukocyte interactions, with coating of target leukocytes by
platelets, thus preventing the binding of selection antibody [28].
There is, thus, a clear need for an efficient and gentle method for
platelet depletion of PBPC products.
Currently used methods for platelet depletion of PBPC products
are based on low speed, successive manual [14,15] or automated
[29] centrifugation which typically result in 80–95% platelet
depletion and more than 90% recovery of leukocytes. Similar
results on cell separation efficiency were found in this study, using
acoustophoresis. However, a direct comparison between the two
separation techniques, using clinical scale PBPC samples, would be
necessary to draw final conclusions. Current, centrifugation based
methods may, despite low g-forces, induce interactions between
platelets and adjacent leukocytes. In acoustophoresis, the size
dependant fractionation provides an instant physical separation of
leukocytes and platelets, thus preventing further aggregate
formation, as shown in this study. In a future clinical setting,
acoustophoresis has the potential to provide an efficient platelet
depletion which, despite an increase in activation level of the few
platelets remaining in the target fraction, will result in a markedly
reduced total number of activated platelets and also minimize
further leukocyte-platelet aggregate formation in PBPC products.
In applications demanding high throughput, several separation
channels can be operated in parallel, similar to the approach
previously used in microchip-based blood washing where a device
comprising eight separation channels in a bifurcation tree was used
to increase the flow rate to 0.5 ml/min [43]. Such an approach
would open up the possibility for ‘in-line’ platelet depletion of
collected PBPC directly following separation in the collection
chamber of the apheresis instrument. This would require a flow
rate of 1–2 ml/min and is thus technically feasible. The instant
physical separation of collected leukocytes and platelets would
prevent platelet activation in further handling of the PBPC
product and, furthermore, enable to simultaneously re-infuse the
acoustophoresis separated platelets to the donor, thus preventing
apheresis-induced thrombocytopenia.
In summary, we conclude that the acoustophoresis technique as
described herein can be utilized to efficiently deplete PBPC
Figure 3. Progenitor cell colony-forming ability. The number of colonies/1,000 plated cells from 9 different PBPC samples and their
corresponding target fractions are presented. The numbers of colonies are given for each single PBPC sample and as median (range) of 4–6
sequentially collected sample portions from each target fraction, respectively.
doi:10.1371/journal.pone.0023074.g003
Table 2. Leukocyte populations.
PBPC sample Target Waste
Morphology
{
Granulo-/monocytes (%) 70 (60–78) 68 (50–73) 12 (0–81)
Lymphocytes (%) 17 (16–28) 20 (15–39) 51 (0–91)
Promyelocytes (%) 11 (1–12) 9 (6–20) 1 (0–1)
Blast cells (%) 2 (1–2) 2 (1–9) 3 (0–8)
Flow cytometry analysis
{
CD34 (%) 2.5 (1.5–3.4) 2.3 (1.0–3.1) 1.6 (1.1–2.8)
CD3 (%) 16 (7.2–24) 17 (9.7–24) 38 (8.3–68)
CD3/4 (%) 9 (3.8–11) 10 (4.1–12) 20 (6.5–35)
CD3/8 (%) 6 (4.9–7.6) 7 (5.0–8.1) 17 (4.9–29)
CD14 (%) 43 (39–47) 45 (40–47) 23 (1.9–40)
CD56 (%) 1.9 (1.6–6) 2.3 (1.5–5.7) 1.4 (1.6–18)
CD19 (%) 2.8 (0.5–5.2) 1.3 (0.3–2.2) 1.0 (0.3–1.6)
Viability (%)
# 98 (97–99) 98 (97–99) 97 (95–98)
{Data are presented as the median (range) of 4 samples (sample no. 2–4 and 7).
{Data are presented as the median (range) of 3 samples (sample no. 2–4).
#Viability was determined using Propidium Iodide (PI) in flow cytometry
analysis.
doi:10.1371/journal.pone.0023074.t002
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cell viability and progenitor cell colony-forming ability. Acousto-
phoresis is, thus, an interesting technology to improve current cell
processing methods, with the potential to efficiently deplete PBPC
products of intact platelets for re-transfusion to the donor, while
preserving the number and function of the collected PBPC in a
future clinical apheresis setting.
Materials and Methods
Ethics Statement
Sampling of patient and donor PBPC products for use in the
current study was approved by the Regional Ethical Review Board
at Lund University. Written informed consent was obtained from
all participants involved in the study.
Figure 4. Platelet activation. Analysis of platelet activation is based on the surface expression of P-selectin (CD62P). Representative dot plots and
histograms from one of five samples are shown. A1) The CD61+, single platelets were gated on low side scatter properties (R1). A2) The cells were
displayed and plotted against anti-CD62P and anti-CD45 to determine the relative number of activated single platelets (CD61+/CD62P+) and to
confirm the exclusion of platelet-leukocyte aggregates. (R2; CD61+/CD62P+/CD45+), respectively. B) The relative number of CD62P+ platelets in the
single platelet fraction (R1) was calculated for each sample by setting the M1 marker in the isotype control histogram (turquoise line). Unstimulated
platelets from buffy coat platelet concentrates (BC, red line), the PBPC samples (green line), the waste fractions (orange line) and from the target
fractions (dark blue line) were analysed (B1). Platelets from the waste fraction and from BC were analysed again after stimulation with TRAP (B2).
doi:10.1371/journal.pone.0023074.g004
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Samples were obtained from PBPC products collected after
standard mobilization treatment of healthy donors (G-CSF,
Neupogen; Amgen, Thousand Oaks, CA, USA) and patients
(protocol specific chemotherapy + G-CSF). Large volume
leukapheresis was performed with a Cobe Spectra (Cobe, Lake-
wood, CO, USA), using the MNC program, version 7.0. On the
day of the leukapheresis, or after a maximum of 24 hours storage,
1 mL of PBPC sample was removed from the collection bag,
analysed using a standard automated hematology analyzer
(Sysmex KX-21N, Sysmex, Kungsbacka, Sweden), and surplus
cells were used for further experimentation.
Figure 5. Platelet activation and aggregate formation. Platelet activation based on the surface expression of P-selectin (CD62P). The median
relative numbers of single platelets expressing CD62P (A) and the median relative numbers of CD61+/CD62P+/CD45+ platelet-leukocyte aggregates
(B), respectively, are given as the median (range) of 5 individual samples (sample no. 11–15).
doi:10.1371/journal.pone.0023074.g005
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The chip was designed to consist of a single acoustophoresis
channel dividing at each end of the chip into a trifurcation with one
central orifice and the laterally dividing branches joining to form a
single side orifice, thus resulting in a chip with two inlets at one end
and two outlets at the other (Figure 1). The silicon acoustophoresis
channel was made by anisotropic wet etching using Potassium
hydroxide (220 g KOH in 550 MilliQ H2O) and sealed with a glass
lid using anodic bonding. The channel width was set to 380 mmt o
match half a wave length resonance of 2 MHz. Silicon tubing with
an inner diameter of 1/16 inches was glued to the inlets and outlets,
to act as docking ports for fluidic tubing.
Acoustophoresis set up
The chip was equipped with three syringe pumps (WPI
SP210iwz, World Precision Instruments, Sarasota, FL, USA)
connected to 5 mL plastic syringes (BD Plastipak Luer-Lok Tip,
Franklin Lakes, NJ, USA) to control the flow through the chip
(Figure 6). Two pumps were connected via Teflon tubing (VWR
Intnl. O.d. 1.54 mm, I.d. 0.05 mm) to the chip outlets and set in
withdrawal mode. The third pump was connected to the chip
central inlet, infusing wash buffer (Dulbecco’s Phosphate Buffered
Saline (PBS), pH 7.4; 1% Bovine Serum Albumin (BSA); 2 mM
Ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA),
all from Sigma-Aldrich). The PBPC sample was connected to the
chip side inlet and entered into the separation channel at a net
flow rate set by the three pumps. A switching valve injector
(25.EPC12W, VICI, Valco Instruments, Houston, TX) was
inserted between the chip outlets and the outlet syringe pumps,
allowing the intermittent connection of sampling loops (Teflon
tubing, 128 ml) to the system and thus, enabling the collection of
outlet samples without syringe pump manipulation. The ultrasonic
standing wave was generated by a piezoelectric transducer (PZ26,
Ferroperm Piezoceramics, Kvistgard, Denmark), which was
operated via an amplifier (Amplifier Research 75A250, South-
erton, PA, USA) by a waveform generator (Agilent 33220A,
Hewlett-Packard Inc., Palo Alto, CA, USA), setting the resonance
frequency to 2 MHz. The delivered electric power was monitored
by a Bird model 5000-EX digital power meter (Bird Electronic
Corporation, Cleveland (Solon), OH, USA) and visual monitoring
of the set up was performed using a Nikon SMZ800 microscope
(LRI Instrument, Lund, Sweden).
Fluidics and sampling procedure
The two pumps in withdrawal mode were set to give a flow rate
through each of the three exit branches of 20 ml/min. The wash
buffer was infused at a flow rate of 40 ml/min, leaving a net flow
rate of 20 ml/min (10 ml/min in each side inlet branch) for the
PBPC sample. The sampling loops were pre-filled with PBS in
order to eliminate air flowing into the system when the loops were
set to collection mode. The PBPC samples were diluted 1:5 in PBS
and connected to the side inlet of the chip. The operational
parameters were tuned by visual inspection of the outlet
trifurcation and set when leukocytes were optimally focused into
the central outlet and platelets were distributed to the lateral
branches (Figure 1B and Movie S1).The sampling loops were
activated and allowed to fill up with separated fluid for 5 minutes.
The loops were disconnected and flushed with air to evacuate the
central outlet loop (target fraction) and the side outlet loop (waste
fraction), respectively. The diluted PBPC samples, the target and
the waste fractions were analyzed for blood cell counts (Sysmex
KX-21N, Sysmex, Kungsbacka, Sweden).
Cell morphology
From each PBPC sample, cytospin slides were prepared from
target and waste fraction by centrifugation of 5,000–10,000 cells
onto glass slides (5 minutes, 750 rpm. Labex Instruments AB,
Go ¨teborg, Sweden) onto glass slides. The cells were stained for
5 minutes with May-Gru ¨nwald solution (May-Gru ¨nwald, Eosin;
Histolab Products, Va ¨stra Fro ¨lunda, Sweden), washed, fixed for
20 minutes in Giemsa (Histolab Products), washed and blotted
dry. The cells were evaluated using a Nikon H 55OL microscope.
Flow cytometry leukocyte analysis
PBPC samples, target and the waste fractions were analysed for
CD342, CD32, CD3/42, CD3/82, CD142, CD562 and
CD19-positive cells, using a four-colour flow cytometer (FACS-
Calibur; BD, Becton Dickinson, San Jose, CA, USA). Fluro-
chrome-labelled monoclonal antibodies were used in different
combinations as follows: anti-CD34 phycoerythrin (PE), anti-
Figure 6. Schematic diagram of the acoustophoresis set up. Two pumps connected to the chip outlets and set in withdrawal mode, and one
pump connected to the chip central inlet, infusing wash buffer were responsible for flow control. The PBPC sample was connected to the chip side
inlet and entered into the separation channel at a net flow rate set by the three pumps. A switching valve injector was inserted between the chip
outlets and the outlet syringe pumps enabling the collection of outlet samples. The ultrasonic standing wave was generated by a piezoelectric
transducer operated via an amplifier by a waveform generator setting the resonance frequency to 2 MHz.
doi:10.1371/journal.pone.0023074.g006
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protein complex (PerCP) or allophycocyanin (APC), anti-CD3
FITC, anti-CD4 APC, anti-CD8 PE, anti-CD56 PE, anti-CD19
PE or PerCPCy5, anti-CD14 PE or PerCP (all BD) and anti-CD15
PE (Becton Dickinson, Pharmingen, San Diego, CA, USA). For
isotype controls, IgG1 (FITC) and IgG1 (PE) were used (BD).
Propidium Iodine (PI, 100 ug/ml, Sigma-Aldrich) was used for
dead cell exclusion. 50,000 events were acquired and data were
analyzed with CellQuest software (BD).
Hematopoietic progenitor cell assays
PBPC samples, target and waste fractions were evaluated for
their colony-forming ability in hematopoietic progenitor cell assays
using standard methylcellulose culture (MACS HSC-CFU media
complete with EPO, Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). Cells were plated at a concentration of 1,000 cells/mL
and incubated for 14 days (Thermo Forma Steri incubator, 37uC,
5% CO2). Hematopoietic progenitor cell colony forming units
(CFU) were enumerated based on standard criteria using an
Olympus IX70 microscope.
Platelet activation
Control samples were obtained from stored (7 days), blood bank
platelet concentrates, which were prepared from pooled buffy-
coats, suspended in platelet additive solution T-SOL
TM (Baxter
Healthcare corp., Deerfield, IL, USA) and depleted of leukocytes
by filtration according to standard blood bank procedures.
Samples were analyzed for platelet cell count (Sysmex KX-21N,
Sysmex, Kungsbacka, Sweden). A number of 20610
6 platelets
from the control samples, the PBPC input samples, the target and
the waste fractions were directly suspended in cold Cellfix (0.5%,
BD biosciences). A number of 20610
6 platelets from the control
samples and the waste fractions were incubated with 20 mM
TRAP (Thrombine Receptor Activator Peptide, stock solution
200 mM, Sigma-Aldrich), for 20 minutes in room temperature,
after which they were suspended in Cellfix as described above.
Control and acoustophoresis samples were washed twice (centri-
fuged at 12006g, for 5 minutes) in PBS and re-suspended in 1 ml
of DBA (PBS+0.2% BSA+0.1% Sodium Azid, Mallinckrodt
Baker, Phillipsburg, NJ, USA). Flowcytometric analysis of CD61
(fibrinogen receptor, platelet specific), CD62P (P-selectin, a-
granule membrane protein expressed on the surface of activated
platelets) and CD45 (leukocytes) was performed. Fluorochrome-
labelled monoclonal antibodies (all BD, Biosciences) were used as
follows: anti-CD61 FITC, anti-CD62P PE and anti CD45 PerCP.
Samples were analysed using a three-color flow cytometer (FACS-
Scan, BD Biosciences). 10 000 events were acquired from each
sample and data were analyzed with CellQuest software (BD)
(Figure 4).
Presentation of results and statistical analysis
Data are presented as median (range) or as mean 6 standard
deviation (SD). Statistical analysis was performed using the Wilcoxon
signed rank test for paired observations and the Wilcoxon log rank sum
test for comparison of two sample groups. For the latter, a two-sided p-
value of ,0.05 was considered significant.
Supporting Information
Movie S1 Movie clip of the separation process taken at
the trifurcation. The larger leukocytes (WBC) have been centered
in the channel by the ultrasonic standing wave and are collected in the
central outlet, while the smaller platelets (PLT) are less acoustically
affected and exit through the side branches.
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